NCT00981409 - The Treatment of Acute Pulmonary Thromboembolism (PE) of GSK576428 (Fondaparinux Sodium) in Japanese Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions

Embolism, Pulmonary

Interventions

DRUG

Fondaparinux sodium

The dose of Fondaparinux will be determined based on a subject's body weight (\<50 kg, 5 mg; 50 to 100 kg, 7.5 mg; \>100 kg, 10 mg) and administered once daily by subcutaneous (SC) injection.

DRUG

unfractionated heparin (UFH)

UFH therapy will be started on Day 1 while adjusting activated partial thromboplastin time (aPTT) to maintain aPTT 1.5 to 2.5 times control.

Trial Locations (27)

440-8510

GSK Investigational Site, Aichi

260-8677

GSK Investigational Site, Chiba

802-8555

GSK Investigational Site, Fukuoka

370-0829

GSK Investigational Site, Gunma

371-8511

GSK Investigational Site, Gunma

060-8543

GSK Investigational Site, Hokkaido

060-8648

GSK Investigational Site, Hokkaido

654-0155

GSK Investigational Site, Hyōgo

305-8576

GSK Investigational Site, Ibaraki

311-3193

GSK Investigational Site, Ibaraki

892-0853

GSK Investigational Site, Kagoshima

860-0008

GSK Investigational Site, Kumamoto

860-8556

GSK Investigational Site, Kumamoto

514-8507

GSK Investigational Site, Mie

390-8621

GSK Investigational Site, Nagano

859-3615

GSK Investigational Site, Nagasaki

951-8520

GSK Investigational Site, Niigata

701-1192

GSK Investigational Site, Okayama

530-8480

GSK Investigational Site, Osaka

540-0006

GSK Investigational Site, Osaka

565-8565

GSK Investigational Site, Osaka